Trial Profile
A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Metformin (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2023 Status changed from recruiting to withdrawn prior to enrolment due to No participant enrollment
- 22 Oct 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2026.
- 22 Oct 2021 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2024.